Should we customize the treatment with interleukin-17A inhibitors for moderate-to-severe psoriasis in the real-world setting?
Kun HuMi ZhangJing YangQiaolin WangMinjia TanSichun DengJunchen ChenWu ZhuWendong ChenYehong KuangXiang ChenPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2022)